Paeds Vivas · clinical-pharmacology-and-therapeutics
Therapeutic drug monitoring — branching viva
Branching viva on therapeutic drug monitoring in children: choosing the vancomycin area-under-the-curve target and sampling time, recognising augmented renal clearance in PICU, and defending the nonlinear Michaelis-Menten kinetics and free-fraction reasoning that govern a toxic phenytoin level in a hypoalbuminaemic child.
On this page & tools
Target exams
Opening — the vancomycin level on the ward
Examiner: A six-year-old on intravenous vancomycin for a complicated MRSA bacteraemia has a trough back. What is your monitoring target, and when should the level have been drawn? [1]
Candidate (model): For serious MRSA infection my target is the 24-hour area under the concentration–time curve over the MIC — an AUC₂₄/MIC of 400 or more — as set by the 2020 ASHP, IDSA, PIDS and SIDP consensus guideline. AUC-guided monitoring, by two timed levels or Bayesian forecasting from a single level, is preferred over a trough-only strategy because it achieves target exposure with less nephrotoxicity. A true trough is drawn within 30 to 60 minutes before the next dose, at steady state — about the fourth dose in an older child — and not during the infusion or from the infusing line. [1]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References4Show ledgerHide ledger
- [1]Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant Staphylococcus aureus Infections: A Revised Consensus Guideline and Review. Clin Infect Dis, 2020.PMID 32658968
- [2]He CY, Ye PP, Liu B, et al. Population Pharmacokinetics and Dosing Optimization of Vancomycin in Infants, Children, and Adolescents with Augmented Renal Clearance. Antimicrob Agents Chemother, 2021.PMID 34339268
- [8]Ludden TM Nonlinear pharmacokinetics: clinical Implications. Clin Pharmacokinet, 1991.PMID 2044328
- [9]Patsalos PN, Zugman M, Lake C, et al. Serum protein binding of 25 antiepileptic drugs in a routine clinical setting: A comparison of free non-protein-bound concentrations. Epilepsia, 2017.PMID 28542801